Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...

Repligen's exclusive partnerships with companies such as DRS Daylight Solutions and Purolite give it a competitive edge in the industry. The company's diverse product line includes pre-packed columns, ...

I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in ...

It is doubtless a positive to see that the Repligen Corporation (NASDAQ:RGEN) share price has gained some 35% in the last three months. But if you look at the last five years the returns have not been ...

A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 11.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...

For the three-month stretch ending in March, Repligen Corporation turned record-breaking revenue of $206.4 million into operating earnings of $0.92 per share. Organic revenue was up 44% year over year ...